YARDLEY, Pa.--(BUSINESS WIRE)--Vensun Pharmaceuticals, Inc., a privately held generic pharmaceutical company, announced today that it has entered into an agreement with ScieGen Pharmaceuticals, Inc. to commercialize 23 prescription generic products. Under the terms of this agreement, once the ANDAs receive final FDA approval, the products will be manufactured and supplied by ScieGen and marketed and distributed exclusively by Vensun. Two of these products have already received final approval with the first product launch under way, and several other product launches expected by year end. According to IMS, the combined annual U.S. sales for these 23 products are approximately $6 billion.
Dr. Pailla Malla Reddy, Chairman and CEO of ScieGen stated, “We are very pleased to enter into this relationship with Vensun and look forward to further expanding our alliance. Vensun has built an impressive infrastructure to support sales operations and we are confident in their ability to market this product portfolio.”
Hey, check out all the research scientist jobs. Post your resume today!
